News Hub | News Direct

African American Heritage Brands Black Radiance and Cross Colours Join Forces For Retro Beauty Collaboration

Black Radiance Beauty

Black Radiance, the leading beauty brand for women of color, has teamed up with Cross Colours, the Afro-centric streetwear brand that embodies the bold spirit of retro hip-hop culture, for an exciting first-ever collaboration. This partnership brings together two trailblazing brands with deep roots in African American culture, uniting to honor their shared heritage by reimagining the bold, expressive spirit of the 80s and 90s hip-hop culture through innovative makeup design. With over 30 years of shaping beauty and fashion for the African American community, the collection draws inspiration from Cross Colours' vibrant color aesthetic, capturing the essence of the hip-hop era. Together, the brands are celebrating a time when music, fashion, and beauty pushed boundaries and defined an era. "This partnership is a full-circle moment for Black Radiance," said K. MacDonald Parris, Vice President of Marketing at Black Radiance. “We are thrilled to work with the iconic label that helped shape hip-hop culture and revolutionized streetwear just as we’ve redefined beauty for Black women. Now, we’ve come together to honor that era and bring it into today’s digital and social world, creating bold new beauty moments that resonate with both the original generation and today’s youth." “We’ve always seen makeup artists creating incredible looks inspired by Cross Colours,” said TJ Walker, Co-Founder of Cross Colours. “That creativity inspired us to give something back to the beauty community, something that reflects the spirit of individuality and self-expression that Cross Colours was built on. Black Radiance shares this passion for celebrating authenticity, making this collaboration feel so natural." “The retro theme of this collection pays homage to the era that birthed our brands and celebrates the deep connection between music, fashion, and beauty,” said Carl Jones, Co-Founder of Cross Colours. “This collection is a celebration of Black beauty in all its forms—it’s about empowerment, individuality, and embracing who you are. Through this collaboration, we continue our commitment to uplifting Black women and redefining beauty standards.” The Black Radiance X Cross Colours collection includes: Cross Colours™ Eye Shadow Palette ($15): A cassette tape-inspired palette with eight talc-free, pigment-rich powders in matte, metallic, and shimmer finishes for bold, vibrant eye looks. Cross Colours™ Mic Drop Mascara ($12): This volume-boosting mascara delivers intense color, featuring a 500+ bristle-packed hourglass brush for clump-free definition. Available in Check 1 Black and Check 2 Blue. Cross Colours™ Paint Palette ($10): A multi-use palette with four creamy, blendable primary colors enriched with Vitamin E and Soybean oil for vibrant face and eye looks. Cross Colours™ Metallic Liquid Lip ($8): A glossy long-wearing formula with bold metallic hues and multidimensional shine, available in Fresh Drip Pink, Vixen Red, and Hyped Up Purple. Cross Colours™ Lipstick Remix ($10): A creamy, ombre-effect lipstick with Murumuru Butter, Vitamin E, and botanical oils for soft, sculpted lips. Available in Gimme A Beat, 3 Divas, and Triple Threat. The Black Radiance x Cross Colours collaboration will be available to shop online at Amazon and select CVS, Target, Walgreens, and Walmart stores. Be sure to follow every Black Radiance x Cross Colours moment on Black Radiance’s Instagram, Facebook, Twitter, and TikTok, and Cross Colours’ Instagram, Facebook, and Twitter. High res images, interviews, and media samples are available upon request. About Black Radiance: For over 30 years, Black Radiance® has recognized, represented, and celebrated the diversity of darker complexions by offering affordable, high-quality cosmetics with uncompromising color, trusted coverage, and formula innovation. Black Radiance empowers and inspires women of color through cosmetics, beauty, and lifestyles. Our mission – to enable Black women worldwide to be even more beautiful. We promise to create both products and experiences that encourage women of color worldwide to embrace, enhance, define, and love their shade of beauty. About Cross Colours: Founded in 1989 by Carl Jones and TJ Walker, Cross Colours revolutionized fashion with its vibrant, socially conscious designs deeply rooted in hip-hop culture. Championing "Clothing Without Prejudice," the brand has been a beacon for Pan-Africanism and Afrocentrism, worn by icons like Will Smith, TLC, and more recently, Rihanna and Cardi B. As the first Black-owned brand to hit $100 million in sales and achieve mass distribution, Cross Colours continues to inspire and empower a new generation, maintaining its commitment to inclusivity and cultural expression. For more information, visit crosscolours.com or follow us @crosscoloursla on Instagram and TikTok. Contact Details Six One Agency Camryn Carlson camryn@six-one.com Black Radiance Sherry West swest@markwins.com

December 20, 2024 10:07 AM Eastern Standard Time

Image

New Alvarez & Marsal Fall 2024 Consumer Sentiment Report Highlighting the Impact of Ongoing Consumer Skepticism on Holiday Plans and Winter Spending

Alvarez & Marsal Consumer and Retail Group

· Since the sharp pullback observed during last year's holiday season, consumers have maintained conservative spending habits. · Consumers are demonstrating greater loyalty to stores over brands, challenging the conventional notion of brand loyalty · Shoppers are expected to pull back their spending across all major holiday spending categories this year · Although in-store shopping remains the primary channel, consumers are increasingly gravitating towards online platforms for their holiday purchases Global professional services firm Alvarez & Marsal’s Consumer and Retail Group (A&M CRG) released its latest consumer report, Consumer Sentiment Survey Fall 2024, which analyzes how shifting economic conditions have shaped consumer spending patterns over the past year and explores anticipated spending behaviors for the next six months. This seventh edition of the bi-annual Consumer Sentiment Report draws from a survey of 2,100+ U.S. adults, demographically representative across gender, age, ethnicity, region and income. The report examines evolving consumer behaviors in response to personal finances and economic conditions. It provides insights into shopping priorities across categories, economic conditions, holiday plans, and other key factors influencing purchase decisions for the upcoming fall season, alongside other relevant consumer trends. These insights help retailers optimize inventory, marketing, and pricing while improving their market position. “In today's cost-conscious market, consumers are doing more research and spending less. Retailers must deliver clear value to win their business,” stated Chad Lusk, Managing Director at Alvarez & Marsal’s Consumer and Retail Group. “Consumers are playing it safe with their wallets these days - the fizzle in their optimism since last spring tells us they tightened their belts after the holidays last year and aren't in a hurry to loosen up again. “ The study found that: Consumer outlook for holiday spending is weaker compared to Fall 2023, as consumers anticipate spending less Inflation, interest rates and the job market are the top three macro- economic trends impacting consumer spending decisions Higher income consumers ($100K+) have relatively consistent spending plans, while lower income brackets are planning to spend 13% less this year Higher income households are prioritizing saving, with plans to increase savings by 4% in households making $100K or more. In contrast, lower income households are planning to save 4% less compared to previous periods As consumers look for savvy ways to decrease holiday spending, lower income consumers (<$100K) will purchase less expensive gifts this year while higher income consumers will find other ways to cut back such as waiting for items to go on sale “This holiday season, retailers should be mindful of consumers' cautious approach to spending and adjust their strategies to better align with holiday shopping behaviors and budgets,“ Lusk advised. “To appeal to value-focused consumers, retailers can optimize their omnichannel experience and pricing structure to match evolving shopper priorities and spending plans.” To download a pdf of Consumer Sentiment Survey Fall 2024, please visit: https://alvarezandmarsal-crg.com/insight/consumer-sentiment-survey-fall-2024/ The Alvarez and Marsal Consumer and Retail Group (CRG) is a management consulting firm that tackles the most complex challenges and advances its clients, people, and communities toward their maximum potential. CRG combines the best of A&M’s broader firm's bias toward action and practicality with deep consumer and retail industry experience. CRG partners with businesses across a wide range of categories including Food & Beverage, Beauty & Personal Care, Grocery, Mass Merchandise, and Apparel & Footwear to drive significant performance improvement. Contact Details David Schneidman dschneidman@alvarezandmarsal.com Company Website https://www.alvarezandmarsal.com/industries/retail/retail

November 21, 2024 03:15 PM Eastern Standard Time

Luxy Hair Launches in the U.S. Amazon Premium Beauty Store

Luxy Hair

Luxy Hair, the #1 leading clip-in hair extensions brand, is proud to announce its debut in the U.S. Amazon Premium Beauty Store. Luxy Hair, part of the Beauty Industry Group portfolio, is expanding its reach by providing easy access to its high-quality, ethically sourced products through one of the world’s largest e-commerce platforms. “We are thrilled to collaborate with Amazon to continue our mission of empowering women to feel confident in their own hair,” said Amy Sveda, President of Luxy Hair. “We are excited to bring our ethically sourced, premium-quality hair solutions to a larger audience, helping more women regain confidence and embrace their hair identity.” Amazon customers can now explore and shop Luxy Hair’s extensive shade range, including hair swatches for easy color-matching. Luxy Hair’s storefront will feature best-selling items including the Classic Clip-In Extensions, Seamless Clip-In Extensions, and Halo® Extensions; customer-loved accessories such as Signature Hair Curler, and TikTok favorite Luxy Hair x Acquired Style Collection; and the newer and fastest growing solutions-based products including Scalp Hair Fill-Ins and Thinning Hair Fill-Ins, directly in Amazon’s U.S. Premium Beauty Store. Since its inception in 2010, Luxy Hair has gained recognition for delivering natural-looking, premium quality, do-it-yourself hair extensions made from 100% ethically sourced Remy human hair. The brand is renowned for its dedication to exceptional customer service and its award-winning shade range that meets various hair needs—from adding instant volume and length to addressing hair thinning and loss. Luxy Hair sets itself apart through its exceptional craftsmanship, unwavering commitment to transparency, and dedication to sustainable practices. By fostering open dialogue about hair loss and challenging the stigma surrounding hair extensions, Luxy Hair creates an inclusive space where women feel empowered, supported, and confident throughout their unique hair journeys. For more information, please visit www.luxyhair.com or @luxyhair on social media. Explore the full range of products at www.amazon.com/luxyhair. About Luxy Hair: The #1 rated hair extensions brand in the world, Luxy Hair is on a mission to take the guesswork out of natural-looking beautiful hair. Made from 100% ethically sourced Remy human hair, Luxy Hair creates premium quality hair extensions for all of life’s moments. Having amassed over 250K customers in more than 165 countries, with a large loyal following, Luxy Hair is renowned for its exceptional customer service and engagement. Luxy Hair is the do-it-yourself solution for anyone, any day, anywhere. About Beauty Industry Group: BIG, established in 2004, is the global market leader for professionally installed hair extensions and related beauty products. BIG's professional products are sold in more than 1,300 stores throughout North America and its collective brands service more than 30,000 salons across 165 countries. BIG has offices in four countries and is headquartered in Salt Lake City, UT. Contact Details Six One Agency Camryn Carlson camryn@six-one.com Luxy Hair Gillian Fetters gillianf@luxyhair.com

October 30, 2024 08:03 AM Eastern Daylight Time

Image

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

Award-Winning Hair Care Brand Design Essentials Pledges $2 Million to Support Historically Black Colleges and Universities

Design Essentials

Design Essentials, the Atlanta-based Black-owned company leading in premium hair care for nearly 35 years, is proud to contribute $1 million dollars to Spelman College in Atlanta towards the launch of their Cosmetic Science Program, and $1 million dollars to Howard University in Washington D.C. for the creation of The Design Essentials Community Fund. As part of its continued commitment to consumers and future leaders, Design Essentials is leveraging its expertise in healthy haircare practices for all hair types to inspire and give back to the next generation of leaders and innovators. The pledges reflect the brands belief in philanthropy through donations and resources to local and international communities. Design Essentials aims to make a meaningful impact through give-back initiatives focused on community enrichment, education and mentorship, while also serving its professional and consumer network. Improving access to resources that cater to Black women and men for career advancement, the brand is continuing to create inclusive and diverse spaces, along with premium expert-backed products for textured hair. Spelman College is a global leader in the education of women of African descent. The partnership will directly contribute to Spelman’s Cosmetic Science Program – the first-ever major of its kind available at an HBCU (Historically Black College and University). The groundbreaking STEM program offers a culturally relevant approach with unique perspectives from Black women through research and working knowledge of trends and innovations, students will explore the use of cosmetics and personal care products, particularly in communities of African descent. The pledge will impact the innovative research and development of products, connecting future chemists with the core consumer to achieve efficacy and representation in the products they use. Howard University is one of the leading research universities dedicated to educating students from diverse backgrounds. The launch of The Design Essentials Community Fund will pave the way for Howard University School of Business students who aspire to become entrepreneurs and business leaders. Cornell McBride, Jr., President of McBride Research Laboratories, Inc. and a Howard University alumna, credits his business acumen to the success of flagship brand Design Essentials over the past two decades. Students will gain access to business training programs, including business pitch competitions, business plan advisory services, marketing and branding bootcamps, capital-raising modules, and opportunities to learn about new software and technology. “We are incredibly honored to support the future leaders at these HBCUs during this moment in history,” states Cornell McBride Jr., President and Chief Executive Officer of McBride Research Laboratories. As a Howard University alum, McBride Jr. is dedicated to keeping the Design Essentials legacy intact by supporting rising leaders in business and beauty industries. “It has always been our mission to create high-quality products that meet the demand of hairstyling needs, leave a footprint in social impact initiatives, and nurture individuals and scholars who will drive inclusion within the beauty industry. By investing in the first-ever cosmetic science program and ongoing entrepreneurial mentorship and career opportunities, we are reinforcing our commitment to education and ensuring that diverse voices are at the forefront of innovation in our industry.” Design Essentials’ pledge marks the start of a broader effort to support HBCUs at a national level and nurture the connection between multicultural haircare and consumers globally. As a legacy brand, Design Essentials serves as a partner in style, fostering relationships with future leaders and brand fans to achieve styling success. For more information on Design Essentials, please visit www.designessentials.com For additional information on Spelman College’s Cosmetics Science Program, please visit https://www.spelman.edu/academics/cosmetic-science/index.html For more information on Howard University, please visit https://howard.edu/ About Design Essentials Design Essentials is a leading provider of premium hair care solutions with nearly 35 years of experience. The brand offers over 80 curated products for all hair types and textures and is committed to delivering innovative, research-driven solutions that cater to both professional and consumer needs. Design Essentials is proud to be minority-owned and operated, with a global reach and a strong commitment to giving back to communities worldwide. Contact Details First and Last PR Camille Gordon camille@firstandlastpr.com First and Last PR Brooke Bhola brooke@firstandlastpr.com Company Website https://designessentials.com/

October 03, 2024 08:00 AM Eastern Daylight Time

Image

Kevel Named to Newsweek’s List of The Top 200 America’s Most Loved Workplaces for 2024

Kevel

Newsweek Magazine today published the annual America’s Top Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI). Kevel has been honored with a place in the top 20, being ranked # 18 out of the 200 companies included in the list. This marks the fourth annual Most Loved Workplace® list. This year, the list has expanded to the Top 200, reflecting companies' growing commitment to prioritizing employee sentiment and creating workplaces that employees love. The results were determined after surveying more than 2.6 million employees from businesses with workforces varying in size from less than 50 to more than 10,000. The list recognizes companies that put respect, caring, and appreciation for their employees at the center of their business model and, in doing so, have earned the loyalty and respect of the people who work for them. “We are so proud about our inclusion on the Most Loved Workplace® list,” said Mike Kohn, Chief People Officer at Kevel. “We have focused on building a people-first organization since our founding, and have used our values as a north star as we scaled our company. We routinely use engagement surveys and qualitative check-ins both to keep a pulse on how we are working as well as to identify trends and insights that enable us to drive actions in support of building a workplace where everyone can thrive.” How positive workers feel about their future at the company, career achievement, how much employer values align with employee values, respect at all levels, and the level of collaboration at the firm were the five critical areas measured to gauge employee sentiment. In addition, areas such as inclusion, diversity, equity and belonging, career development, and company leadership were identified and analyzed in relation to the five critical areas measured. “It’s inspiring to see the list expand this year to 200 companies, a clear indication that organizations are truly committed to creating workplaces where employees feel valued and connected. We’re thrilled to celebrate their achievements as this recognition continues to grow.” - Nancy Cooper, Newsweek’s Global Editor in Chief To view Kevel’s ranking and the top honored companies view the Top 20 Most Loved Workplaces in America or view the full list of the 2024 America’s Top 200 Most Loved Workplaces®. About Kevel Kevel powers world-class retail media networks with the Retail Media Cloud™. With the combination of the Kevel Ad Server and Kevel Audience, multi-brand retailers, marketplaces, and ecommerce companies can launch limitless ad formats and unique targeting segments online and in-store, all with closed-loop attribution. Kevel believes that every digital retailer should have the capability to scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Klarna, Delivery Hero, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media network with Kevel. The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com. About Newsweek Newsweek is the modern global digital news organization built around the iconic, over 90-year-old American magazine. Newsweek reaches 100 million people each month with its thought-provoking news, opinion, images, graphics, and video delivered across a dozen print and digital platforms. Headquartered in New York City, Newsweek also publishes international editions in EMEA and Asia. About Best Practice Institute Best Practice Institute is an award-winning leadership and organization development center, benchmark research company, think tank, and solutions provider. BPI is the only certifying body for Most Loved Workplace® and conducted the original research to create the model and criteria for becoming a Most Loved Workplace®. BPI’s research proves that Most Loved Workplaces® produce 3-4 times better customer service, employee performance, and retention than companies not loved by their employees. For more information on how to apply to become a certified Most Loved Workplace, go to: http://www.mostlovedworkplace.com Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com

October 02, 2024 10:00 AM Eastern Daylight Time

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

COLORESCIENCE® INTRODUCES TOTAL LASH™ MASCARA

Colorescience

Colorescience®, a leading dermatologist-recommended specialty skincare company, is launching Total Lash™ Mascara, an innovative, new all-in-one lash serum, conditioner and mascara that immediately enhances the appearance of lash length and volume for a vibrant, eye-opening effect. With every application, this clinically tested formula works to improve lash health with a blend of peptides and botanicals that nourishes the lashes while helping support the natural lash cycle for healthier, stronger, fuller and longer looking lashes. The Total Lash™ ingredient complex uses gentle, prostaglandin analogue-free ingredients and has been ophthalmology tested and confirmed to be safe for sensitive eyes and contact lens wearers. This formula is ideal for those who want to restore and improve their natural lashes, especially after discontinuing lash extensions, false lashes, or other lash procedures. Dr.Tanya Khan, Oculoplastic Surgeon and Board-Certified Ophthalmologist, led the clinical study. After a 12-week clinical trial with daily usage of Total Lash Mascara 90% of subjects reported their lashes looked longer. As measured by Dr. Khan, lashes were on average 24% longer compared to baseline. Over 92% of subjects reported less lash breakage and 94% reported lashes appeared fuller, thicker, and fluffier after twelve weeks of usage. Recalling these results, Dr. Khan shared, “During the clinical study, it became clear to me that patients were readily achieving their desired results of lash growth, density, thickness, and darkness when using the Total Lash™ product once per day. As an oculoplastic surgeon and ophthalmologist, I am even more amazed that the formula is well-tolerated by sensitive eyes and does not cause irritation or discoloration of the delicate skin around the eye area. I look forward to offering this product to my patients as a safe, effective, and gentle daily option that delivers lash enhancement without prostaglandins or extensions.” This multi-benefit formula enhances the appearance of length and volume, nourishes and strengthens the lashes and supports lash growth. Proven peptide Myristoyl Pentapeptide-17 stimulates the hair follicle to help support continued growth while botanical extracts optimize root health and help promote continued growth for longer, fuller looking lashes. The results are a visibly denser, more defined lash line and longer lashes that are hydrated and nourished. Panthenol and jojoba seed oil condition and nourish lashes to reduce breakage helping strengthen and prolong length and volume. Lastly, the formula immediately enhances lashes upon application while providing all-day smudge-free wear. This tubing mascara wraps each lash in a rich black iron oxide mineral pigment, making this dye-free formula ideal for sensitive eyes. Patricia Boland, VP of Research & Development at Colorescience says, “We created this formula with the tubing feature because our goal is always to treat and improve while delivering immediate enhancement and optimal wear. The skin around the eyes is especially thin and delicate, so extensive rubbing during removal of products can contribute to irritation. Instead, our Total Lash Mascara envelops each lash with our clinically proven treatment complex while maximizing wear-time, and the product removes effortlessly with warm water and a favorite cleanser.” ABOUT COLORESCIENCE Colorescience ®, the leading innovator in all-mineral sun protection, delivers transformational skincare solutions through wearable multifunctional products that provide immediate confidence and long-term visible results. Crafted for users who know that great results require daily skincare and protection, Colorescience ® uses cutting-edge technology and clinically tested formulas to ensure efficacy and provide reassurance to people of all ages, skin types, and concerns. Colorescience ® products speak for themselves through their wearability, published clinical studies, and skin-healthy ingredients. For more information please contact: Project MM, meredith@projectmmnyc.com Contact Details Meredith Winfrey meredith@projectmmnyc.com Company Website https://www.colorescience.com

October 01, 2024 08:00 AM Eastern Daylight Time

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time